OR WAIT 15 SECS
The agency publishes draft guidance on assay development and validation for immunogenicity testing.
On April 22, 2016, FDA released Assay Development and Validation for Immunogenicity Testing of Therapeutic Protein Products, Draft Guidance. The guidance addresses the development and validation of immune assays for assessment of the immunogenicity of therapeutic protein products during clinical trials. The guidance provides recommendations for the development and validation of screening assays, confirmatory assays, titering assays, and neutralization assays for detection of anti-drug antibodies (ADA) and, on a case-by-case basis, some combination products. The guidance does not apply to in vitro diagnostic products and does not address product and patient risk factors that may contribute to immunogenicity.
Specifically, the guidance discusses assay design elements including testing strategies such as a multi-tiered testing approach, immunoglobulin isotypes, and epitope specificity. The following are also addressed:
Assay development information provided addresses the following:
The assay validation section covers general considerations and recommendations for validation of screening, confirmatory, titering, and neutralization assays. Additional sections address implementation of assay testing and documentation.
Related Content:Manufacturing, Monoclonal Antibodies | Manufacturing | Industry News | News | Quality/GMPs | Biopharmaceutical Analysis | API Synthesis and Manufacturing, Large Molecule | Biologic Drugs in Development | Regulatory Authority Actions | Process Validation | Drug Substance Analysis | Development